prophylaxis; ceftriaxone; esophageal variceal hemorrhage Background/purpose: Although prophylactic antibiotics have been recommended for cirrhotic patients with upper gastrointestinal bleeding, the duration of its use remains an inconclusive issue. We designed this study to investigate the duration of antibiotic prophylaxis for cirrhotic patients with acute esophageal variceal bleeding. Methods: We enrolled those patients suffering from acute esophageal variceal bleeding and receiving band ligation. They were randomly allocated to two groups to receive prophylactic antibiotics; Group I: receiving intravenous ceftriaxone 500 mg every 12 hours for 3 days, and Group II: same regimen for 7 days. We used rebleeding rate within 14 days as the primary end point and also evaluated the survival rate within 28 days and the amount of transfusion during admission. Results: There were 38 patients in Group I and 33 patients in Group II that completed the study course for analysis. Overall, there was no significant difference in the baseline characteristics between these two groups. There were three patients both in Group I and Group II who developed rebleeding within 14 days (8% vs. 9%, p > 0.99). There was also no difference between Group I and Group II in transfusion amount (2.71 AE 2.84 units vs. 3.18 AE 4.07, p Z 0.839) and survival rate in 28 days (100 vs. 97%, p Z 0.465). Conclusion: Our small scale study demonstrated that there was no difference in the rebleeding rate between 3-day and 7-day ceftriaxone prophylaxis for cirrhotic patients with acute
Introduction
Infection is commonly encountered in cirrhotic patients and is associated with significant morbidities and mortality. The infection rate was reported to be 32e66% in patients with upper gastrointestinal bleeding. 1, 2 Therefore, in recent times, prophylactic antibiotics have been routinely recommended for cirrhotic patients with upper gastrointestinal bleeding. 3e5 Esophagogastric variceal hemorrhage is an important complication in cirrhotic patients characterized by high rebleeding rate and mortality. 6 These patients are particularly vulnerable to bacterial infections, 7, 8 and such infections further result in increased rebleeding rates and higher mortality in this group. 9, 10 Although prophylactic antibiotics have been recommended for cirrhotic patients with upper gastrointestinal bleeding, the regimen and duration of its use remain an inconclusive issue. 11, 12 In recent times quinolones and third generation cephalosporins, especially ceftriaxone, have been more often used for prophyalxis. 6, 13 The duration for antibiotic usage varies in the literature, ranging from 3 days to 10 days. 3, 5 Prophylaxis use for 7 days was more often used and recommended. 4e6 In a survey of infections in cirrhotic patients with upper gastrointestinal bleeding performed by Bernard et al 1 , most infections occurred in the first 5 days after admission and half within the first 48 hours. Considering the cost-effectiveness and drug resistance issues, the necessity for such prophylaxis for 7 days might need to be reevaluated. Therefore, we designed this study to investigate the duration of antibiotic prophylaxis for cirrhotic patients with acute esophageal variceal bleeding.
Methods
We enrolled patients suffering from acute esophageal variceal bleeding documented by endoscopic examination and they received endoscopic variceal ligation during this session. The endoscopic variceal ligation was mostly performed by experienced endoscopists or alternatively, by 2 nd year fellows supervised by experienced endoscopists. We use a multiband ligator loaded with seven bands for ligation. Those who had the following signs suggestive of infection were excluded, including fever >37. 5 C, white blood cell count >15000 mm 3 or immature neutrophils >500 mm 3 , polymorphonuclear cell count >250/mm 3 in ascitic fluid, >15 leukocyte count per high power filed in urinalysis, and suspected pneumonia in chest x-rays. 14 Endoscopy was performed within 24 hours after the arrival to the emergency department. We excluded those who had received antibiotics within 2 weeks, were <18 years old, pregnant, allergic to ceftrioxone, or had malignacy other than hepatocellular carcinoma.
After receiving good explanations and giving their consent, these patients were randomly allocated to two groups and received prophylactic antibiotics after endoscopic examination; Group I: receiving ceftriaxone 500 mg (Rocephin, Roche, Kaiseraugst, Switzerland) intravenous bolus stat and then every 12 hours for 3 days; and Group II: receiving ceftriaxone 500 mg intravenous bolus stat and then every 12 hours for 7 days. We used simple randomization to allocate these patients and drew names from an envelope with a 1:1 ratio to allocate them to either Group I or Group II. They all received intravenous glypressin 1 mg every 6 hours for 3 days. They started to feed on the 2 nd day if not contraindicated. The second endoscopic treatment for esophageal varices was performed, if planned by their attending physician, 2 weeks later. We recorded the demographic data, vital signs, comorbidity (including coronary artery disease, heart failure, cerebrovascular accident, chronic obstructive pulmonary disease, and uremia), presence of hepatocellular carcinoma or portal vein thrombosis; checked hemogram, urinalysis, chest x-ray, ascites routine (if apparent ascites existed), classification of variceal size, and ChildePugh classification. We monitored the events of rebleeding, infection, and transfusion amount after enrollment. If there were new infection signs lasting >24 hours in patients after enrollment and prophylactic antibiotic use, they would be eliminated from this study. We used rebleeding rate within 14 days as the primary end point. It is defined as the following events after initial stabilization of vital signs for 24 hours: (1) recurrence of hematemesis or bloody stool; and (2) tarry stool and need of transfusion more than two units of blood, or with systolic pressure <100 mmHg or pulse rate >100 per minute. The secondary end points were survival rate within 28 days and the amount of transfusion during admission.
All data were analyzed with the statistical software SPSS version 20 (SPSS Inc., Chicago, IL, USA) for windows. Regarding the baseline characteristics, the categorical data were compared with Chi-square test or Fisher's exact test. The continuous data were compared with the ManneWhitney U-test. We used Fisher's exact test to examine the differences of rebleeding rate and survival rate within 28 days. ManneWhitney U-test was used to examine the difference in transfusion amount during admission.
Results
From May 2009 to Jan 2013, there were 168 patients screened for eligibility. Sixty-five patients did not give their consent and 24 patients were excluded because of infection signs. There were 79 patients enrolled; 40 were allocated to Group I and 39 were allocated to Group II. Two patients in Group I dropped out from this study, one because of withdrawal of consent and one because of persistent fever; six patients in Group II dropped out from this study, three because of withdrawal of consent, two because of persistent fever, and one because of pneumonia. There were 38 patients in Group I and 33 patients in Group II that completed the study course and were available for analysis (Figure 1 ). There were 35 male patients and 3 female patients in Group I with mean age of 54.7 years; there were 29 male patients and 4 female patients in Group II with a mean age of 50.0 years. There were no difference for the age (p Z 0.121) and gender (p Z 0.697) between these two groups. For etiology of cirrhosis, there were 14 patients with hepatitis B, 11 patients with hepatitis C, and 24 patients were alcoholic in Group I. There were 13 patients with hepatitis B, 6 patients with hepatitis C, and 19 patients were alcoholic in Group II. There were no significant differences in the mean number of comorbidities between Group I (0.66 AE 0.71) and Group II (0.42 AE 0.50), p Z 0.185.
There were also no significant differences between these two groups for patients with hepatocellular carcinoma (10 in Group I, 6 in Group II, p Z 0.57), portal vein thrombosis (one in Group I, two in Group II, p Z 0.594), and ascites (19 in both Group I and Group II, p Z 0.635).
The mean systolic blood pressure of the Group I was 122.84 AE 26.12 mmHg, the mean heart rate was 96.55 AE 20.73 beats per minutes; the mean systolic blood pressure of the Group II was 123.33 AE 21.58 mmHg, the mean heart rate was 101.36 AE 27.90 beats per minutes. There were no differences for the systolic blood pressure (p Z 0.751) and heart rate (p Z 0.381) between these two groups. There were two patients (5.3%) in Group I and one patient (3.0%) using aspirin and showed no difference (p > 0.99). There was no patient using anticoagulant. In Group I, the hemoglobin level was 9.82 AE 2.02 g/dL, white blood cell count was 7. Figure 1 Patient participation and study course.
1.3 AE 0.3. The difference between these two groups was significant for hemoglobin level (p Z 0.028), not significant for white cell count (p Z 0.665) and platelet count (p Z 0.343), and prothrombin time INR (p Z 0.300). In Group I, the serum creatinine was 1.17 AE 1.02 mg/dL, the serum albumin was 3.18 AE 0.56 g/dL, the ChildePugh classification was A in 17 patients (45%), B in 19 patients (50%), and C in two patients (5%); In Group II, the serum creatinine was 0.78 AE 0.39 mg/dL, the serum albumin was 2.99 AE 0.474 g/dL, the ChildePugh classification was A in 10 patients (30%), B in 17 patients (52%), and C in six patients (18%). The difference between these two groups was significant for serum creatinine (p Z 0.049), not significant for serum albumin (p Z 0.103), and ChildePugh classification (p Z 0.155). The slightly higher mean creatinine level in Group I rendered the baseline condition favoring Group II, and the slightly lower mean hemoglobin level in Group II rendered the baseline condition favoring Group I. Overall, there was no significant difference at the baseline between these two groups ( Table 1 ). There was also no difference of size of esophageal varices, frequency of active bleeding (32% vs. 36%, p Z 0.802) during endoscopic examination and mean band number used (4.9 AE 1.5 vs. 5.2 AE 1.4, p Z 0.317) between these two groups ( Table 2 ).
There were both three patients in Group I (8%) and in Group II (9%) who developed rebleeding within 14 days. The mean transfusion amount was 2.71 AE 2.84 units in Group I and 3.18 AE 4.07 units in Group II. No patient in Group I and one patient in Group II died within 28 days. There were no differences between Group I and Group II for rebleeding rate (p > 0.99), transfusion amount (p Z 0.839), and 28 day survival (p Z 0.465) ( Table 3) . Of the two patients in Group I and six patients in Group II that dropped out from the study, none developed rebleeding episodes or died within 28 days of their initial enrollment. We performed multiple logistic regression to analyze the risk factors for rebleeding, and only found shock on admission to be an independent factor for rebleeding (p Z 0.022). All other factors were not significant. Almost half of the study patients did not regularly attend our outpatient clinic several months later, therefore we do not have long term follow up data for analysis.
Discussion
Acute variceal bleeding is a serious complication in cirrhotic patients and used to be associated with very high mortality rates. However, the mortality rate decreased markedly over the past two decades, probably mainly because of the application of vasoactive agent, endoscopic therapy, and antibiotic prophylaxis. 6, 15 The clinical outcomes of cirrhotic patients with chronic viral infections are further improved by active treatment of underlying viral hepatitis. 16 The in-hospital mortality rate was even reported to reach 0 in ChildePugh Class A and B cirrhotic patients in 2000. 15 Our present study also showed a low mortality in patients with acute esophageal variceal bleeding and only one out of these 71 patients died within 28 days of enrollment. Besides prophylaxis with ceftriaxone, all of our patients received intravenous glypressin and endoscopic variceal ligation. Most of these patients belonged to ChildePugh Classes A and B (95% in Group I and 82% in Group II). These factors might contribute to the relatively good survival rates in the patients of our study. Bacterial infections are frequent complications in patients with cirrhosis, with an incidence of w32% on and during admission. 7 These patients are predisposed to infection due to impaired immune function, increased passage of bacteria from the gut (bacterial translocation), and bacterial overgrowth. 17 The immune dysfunction in cirrhotic patients is multifactorial and is probably due to a decrease in bactericidal activity of phagocytic cells, complement level, and impaired function of the reticuloendothelial system which is caused mainly by portosystemic shunting and impaired Kupffer's cell phagocytic activity. 17 Bacterial translocation refers to migration of bacteria or bacterial products from the lumen of intestines to extraintestinal sites. Several mechanisms contribute to bacterial translocation in cirrhotic patients, including intestinal bacterial overgrowth, intestinal motility disturbances, decreased immunity, and impaired intestinal barrier function, as reflected by increased intestinal permeability. 17, 18 During hemorrhage, the barrier function of the gastrointestinal tract might be impaired and the intestinal permeability could be increased. Kim et al 18 reported that increased intestinal permeability is a predictor of bacterial infection in patients with decompensated liver cirrhosis and hemorrhage. Moreover, endoscopic treatment with band ligation is reported to be associated with 8.8% of bacteremia. Considering the development of mucosal defects following variceal ligation, the true frequency of bacteremia might be higher. 19 Prophylactic antibiotics have been routinely recommended for cirrhotic patients with upper gastrointestinal bleeding in recent years.
3e6, 20 Several studies have reported that antibiotic prophylaxis could reduce the rebleeding rate in cirrhotic patients with acute variceal hemorrhage. 8, 21, 22 Quinolones and third generation cephalosporins have been more often reported for prophylaxis, including oral norfloxacin, intravenous ciprofloxacin, and ceftiraxone. 8,14,21e23 Intravenous ceftriaxone is preferred for prophylaxis in patients with more severe liver disease. 6, 13, 14, 24 Wu et al 25 reported that intravenous cefazolin could achieve similar prophylactic effects for acute variceal hemorrhage compared with ceftriaxone in ChildePugh Class A patients.
Short term prophylactic antibiotics have been recommended for cirrhotic patients with variceal hemorrhage. 6, 26 The duration for prophylactic antibiotic use was variable in the literature, ranging from 3 to 10 days, and 7 days was more often used and recommended.
3e6,11 However, in this survey of infections in cirrhotic patients with upper gastrointestinal bleeding performed by Bernard et al, 1 most infections occurred in the first 5 days after admission and half within the first 48 hours. Bleichner et al 27 reported 32 (22%) out of 149 patients admitted to the intensive care unit had shown infection within 48 hours of admission. In our small scale study, there were three patients in Group I (8%) and in Group II (9%) who developed rebleeding within 14 days, and no significant difference was found. There was also no difference in the 28-day mortality between these two groups. Another issue is when to start antibiotic prophylaxis. Brown et al 28 reported antibiotics administrated up to 8 hours following endoscopy were associated with improved survival at 28 day in variceal hemorrhage.
There are several limitations in the current study. The case number is relatively small to draw a strong conclusion. It was carried out in only one hospital and the studied results might not generalize for all other practice appropriately. More than half of the invited candidates initially were excluded due to signs of infection and lack of consent, and they were likely to have more severe diseases. Those who were enrolled were in a relatively more stable condition. Therefore, our results might not be applicable to patients with more severe liver disease and variceal bleeding. Further large scale studies, maybe in a multicenter design, are warranted to validate our results.
In conclusion, our small scale study demonstrated that there was no difference in the rebleeding rate between 3-day and 7-day ceftriaxone prophylaxis for cirrhotic patients with acute esophageal variceal bleeding. There was also no difference in 28-day mortality between these two groups.
